But if you are investing on the ASX, there is one obvious challenge. Buffett does not invest here, and we do not know which Australian shares he would choose.

That said, we do know how he thinks.

And that gives us a useful framework for building a Buffett-inspired portfolio using ASX shares.

Strong competitive advantages

One of Buffett's core principles is investing in companies with durable competitive advantages, often referred to as economic moats.

These are businesses that are difficult for competitors to replicate. This might be due to brand strength, scale, intellectual property, or deep integration into customer operations.

On the ASX, examples could include companies like CSL Ltd (ASX: CSL), which benefits from its global scale and complex plasma network, or REA Group Ltd (ASX: REA), which dominates online real estate listings in Australia.

These types of businesses are often able to maintain pricing power and deliver consistent returns over time.

Look for consistent earnings and strong returns

Warren Buffett has always preferred companies that generate reliable profits.

Rather than chasing speculative growth, he looks for businesses that can steadily grow earnings year after year. High returns on capital and strong cash flow are often key indicators.

ASX companies like Cochlear Ltd (ASX: COH) and ResMed Inc (ASX: RMD) fit this mould, with established products, global demand, and recurring revenue streams.

The goal is to own businesses that perform well across different economic conditions.

Keep it simple and understandable

Another hallmark of Buffett's approach is simplicity.

He invests in businesses he understands. This often means avoiding overly complex or speculative industries.

For ASX investors, this could translate to focusing on companies with clear business models and predictable revenue streams.

Retailers, healthcare companies, and infrastructure businesses can often be easier to understand than highly speculative sectors.

This might mean Woolworths Group Ltd (ASX: WOW), APA Group (ASX: APA), and Wesfarmers Ltd (ASX: WES).

Think long term

Warren Buffett is famous for his long-term mindset.

He has often said his favourite holding period is "forever." This reflects his belief in owning great businesses and allowing compounding to do the work.

A Buffett-inspired ASX share portfolio should be built with a similar mindset. Instead of reacting to short-term market movements, the focus should be on holding quality companies for many years.

Avoid overpaying

Even the best business is not a good investment at the wrong price.

Buffett looks for opportunities to buy high-quality companies at reasonable valuations. This often means being patient and waiting for periods of market weakness.

For ASX share investors, this could involve building a watchlist and being ready to act when quality shares fall out of favour.

Foolish takeaway

We may never know exactly which ASX shares Buffett would buy.

But by focusing on competitive advantages, consistent earnings, simplicity, and long-term thinking, investors can build a portfolio that reflects his philosophy.

It is about applying the principles that made him successful to our own portfolios.

The post How to build a Warren Buffett-inspired ASX share portfolio appeared first on The Motley Fool Australia.

It comes down to a few simple principles. Investing consistently, focusing on quality, and giving your money enough time to grow.

Here is how it can work.

Start with a clear plan

The foundation of wealth building is consistency.

Investing $1,000 every month into ASX shares creates a steady flow of capital into your portfolio. That is $12,000 per year, regardless of what the market is doing.

This approach removes the pressure of trying to pick the perfect moment to invest. Instead, you are building momentum through regular contributions.

Over time, this discipline becomes one of your biggest advantages.

Aiming for a 10% return

A 10% annual return is a useful benchmark.

It is broadly in line with long-term equity market returns and provides a realistic foundation for planning. While markets will not deliver this every year, it is a reasonable long-term expectation.

At this rate, investing $1,000 per month could grow to approximately $200,000 in around 10 years, and $725,000 in 20 years.

Stretch that out to 30 years, and the portfolio could exceed $2 million.

This is where the power of compounding becomes clear.

How to aim for strong returns

There are no guarantees in investing, but there are ways to tilt the odds in your favour.

Focusing on high-quality ASX shares with strong earnings, competitive advantages, and long growth runways can improve your chances of achieving solid returns over time.

ASX share examples include ResMed Inc. (ASX: RMD), REA Group Ltd (ASX: REA), Wesfarmers Ltd (ASX: WES), and Cochlear Ltd (ASX: COH).

It can also help to learn from some of the best investors in history. For example, Warren Buffett has delivered average annual returns of close to 20% over several decades for Berkshire Hathaway (NYSE: BRK.B).

While matching that level of performance is unlikely for most investors, his approach offers valuable lessons. Focus on quality, stay disciplined, and think long term.

Applying these principles can help investors move closer to their goals, even if returns are more modest.

Stay invested and let compounding work

One of the biggest drivers of wealth is time.

The longer your money stays invested, the more opportunity it has to grow. Returns begin generating their own returns, creating a compounding effect that accelerates over time.

This is why staying invested through market cycles is so important.

Short-term volatility can be uncomfortable, but it is often part of the journey toward long-term gains.

Foolish takeaway

Building massive wealth with ASX shares is certainly possible.

By investing $1,000 each month, aiming for solid long-term returns, and staying consistent, it is possible to create a portfolio that grows far beyond what many expect.

The key is to build something steadily, and let time do the heavy lifting.

The post How to build massive wealth with ASX shares appeared first on The Motley Fool Australia.

Not just companies with strong recent performance, but businesses with durable advantages, long growth runways, and the ability to keep compounding over time.

Here are three ASX shares that fit that description and could be worth a closer look following recent share price weakness.

Cochlear Ltd (ASX: COH)

The first ASX share that stands out is Cochlear. It is a medical device company that operates a highly specialised global ecosystem built around hearing implants.

What makes it a quality business is not just its technology leadership, but the longevity of its customer relationships. Once a patient enters the system, they often remain within it for decades through upgrades, servicing, and support.

This creates a steady and growing revenue base that is less dependent on constant new customer acquisition.

With hearing loss becoming more prevalent globally and access to treatment still expanding, Cochlear has a long runway ahead. For investors focused on quality, that combination of recurring revenue and structural demand is hard to ignore.

Life360 Inc (ASX: 360)

Another ASX share that could appeal to quality-focused investors is Life360.

This family safety technology company has been growing at a rapid rate for many years and has around 100 million monthly active users (MAUs) now.

From these users, the company is generating significant subscription revenues and a growing stream of advertising income.

And with management confident that its strong growth can continue in 2026, the future is looking bright for this one. This is especially the case given its plans to expand its offering into pet tracking and other areas.

The company is essentially building a product that integrates into everyday life. And that kind of engagement can be a powerful foundation for long-term value creation.

Pro Medicus Ltd (ASX: PME)

A third ASX share that fits firmly in the quality category is Pro Medicus.

Pro Medicus operates in medical imaging software, but what sets it apart is its business model.

The company focuses on winning large, long-term contracts with leading hospitals and healthcare providers. Once embedded, its solutions become critical to operations, creating high switching costs and strong customer retention.

What is particularly compelling is its ability to scale without a corresponding increase in costs. This has led to exceptional margins and strong cash generation.

Despite already delivering significant growth, Pro Medicus continues to win new contracts globally, particularly in the United States.

And with its shares down heavily from their highs, now could be an opportune time to invest for the long term.

The post 3 high-quality ASX shares to buy while they are cheap appeared first on The Motley Fool Australia.

Will the market be able to bounce back on Monday? Here are five things to watch:

ASX 200 expected to jump

The Australian share market looks set for a strong start to the week despite a mixed finish on Wall Street on Friday. According to the latest SPI futures, the ASX 200 is expected to open the day 70 points or 0.75% higher. In the United States, the Dow Jones was down 0.55%, the S&P 500 dropped 0.1%, and the Nasdaq rose 0.35%.

Oil prices ease

It could be a subdued start to the week for ASX 200 energy shares Santos Ltd (ASX: STO) and Woodside Energy Group Ltd (ASX: WDS) after oil prices eased on Friday night. According to Bloomberg, the WTI crude oil price was down 1.23% to US$96.57 a barrel and the Brent crude oil price was down 0.75% to US$112.57 a barrel. This may have been driven by optimism over peace talks between the US and Iran.

Dividends being paid

A couple more ASX 200 shares will be rewarding their shareholders with dividend payments on Monday. This includes hearing solutions company Cochlear Ltd (ASX: COH) and auto listings giant CAR Group Limited (ASX: CAR). They will be paying partially franked dividends of $2.15 per share and 42.5 cents per share, respectively, later today.

Gold price slides

ASX 200 gold shares including Newmont Corporation (ASX: NEM) and Northern Star Resources Ltd (ASX: NST) could have a soft start to the week after the gold price fell on Friday night. According to CNBC, the gold futures price was down 0.65% to US$4,787.4 an ounce. This may also have been driven by news of peace talks between the US and Iran.

Hold Orora shares

Morgans isn't a buyer of Orora Ltd (ASX: ORA) shares despite their heavy decline last week. The broker has retained its hold rating with a heavily reduced price target of $1.55 (from $2.30). It prefers fellow packaging company Amcor (ASX: AMC) and has a buy rating and $76.00 price target on its shares. It said: "Given the ongoing uncertainty surrounding the conflict in the Middle East, visibility on the timing of a potential restart at the RAK facility remains limited. In addition, global consumer confidence and spirits demand have already been negatively affected by the conflict and may remain subdued for some time, even in the event of a near-term resolution. Given this uncertainty, we believe it is prudent to await further updates before reassessing our view. Within the Packaging sector, our preference remains Amcor (AMC, BUY, $76.00 TP)."

The post 5 things to watch on the ASX 200 on Monday appeared first on The Motley Fool Australia.

But from time to time, even the best companies fall out of favour.

Right now, a handful of ASX blue chips appear to be in that position. Here are three that could be worth a closer look.

CSL Ltd (ASX: CSL)

CSL is widely regarded as one of Australia's highest-quality companies, but the biotech giant's shares have come under pressure in recent times.

This has been driven by earnings misses, margin pressures, a tough operating environment, and leadership changes.

However, these are largely transitional issues rather than structural ones.

CSL still operates a global leader in plasma therapies and vaccines, with strong demand drivers linked to ageing populations and rising healthcare needs. As plasma collection normalises and efficiencies improve, there is potential for margins to recover.

For long-term investors, this could be one of those rare opportunities to buy a premium healthcare business at a more reasonable price.

Cochlear Ltd (ASX: COH)

Another ASX blue chip that could be looking attractive is Cochlear.

Short-term concerns around softer demand have weighed on sentiment. But this does not change the underlying demand for hearing solutions.

Cochlear benefits from a powerful structural tailwind. Hearing loss is a growing global issue, and access to treatment is still underpenetrated in many regions.

The company also enjoys a strong competitive position, supported by technology leadership and a global distribution network.

For investors willing to look beyond near-term noise, Cochlear's long-term growth story appears firmly intact.

Treasury Wine Estates Ltd (ASX: TWE)

A third ASX blue chip that may be undervalued is Treasury Wine Estates.

The company has faced a number of challenges in recent years, including shifting consumer preferences and disruptions to key export markets. These issues have weighed on its share price and created uncertainty around its outlook.

However, Treasury Wine is in the process of reshaping its portfolio.

The focus is increasingly on premium and luxury brands, where margins are higher and demand tends to be more resilient. This shift is helping the company reduce reliance on lower-margin products and improve the quality of its earnings.

In addition, improving trade dynamics and stabilising conditions in key markets could provide a tailwind over time.

While not without risks, Treasury Wine Estates could offer a compelling turnaround opportunity for patient investors.

The post These ASX blue chips now look too cheap to ignore appeared first on The Motley Fool Australia.

With that in mind, here are three ASX shares that could be well suited to a long-term retirement portfolio.

Cochlear Ltd (ASX: COH)

The first ASX share that could be a top retirement pick is Cochlear.

Rather than thinking of Cochlear purely as a healthcare company, it can also be viewed as a global installed-base story. Once a patient receives a cochlear implant, they typically remain within the ecosystem for life, purchasing upgrades, sound processors, and ongoing services.

This creates a level of revenue visibility that many companies simply do not have.

On top of this, Cochlear continues to expand access to hearing solutions across emerging markets, where penetration rates remain low. As healthcare systems develop and awareness improves, more patients are entering the treatment funnel.

For retirement investors, this combination of recurring revenue and long-term demand growth could make Cochlear a reliable compounder over time. The recent launch of a new best-in-class product also arguably brightens the near-term outlook.

Macquarie Group Ltd (ASX: MQG)

Another ASX share that could be worth considering for a retirement portfolio is Macquarie Group.

While many investors think of Macquarie as an investment bank, its real strength lies in its ability to identify and scale opportunities in global infrastructure, energy, and asset management.

Macquarie has built a reputation for turning complex, capital-intensive projects into long-term earnings streams. Whether it is renewable energy platforms, infrastructure assets, or private markets funds, the group has consistently found ways to monetise global trends.

Importantly for retirement portfolios, Macquarie's earnings are not tied to a single cycle. Its diversified operations mean that when one segment slows, another often steps up.

With the ongoing global push into energy transition, digital infrastructure, and private assets, Macquarie appears well placed to keep growing its earnings and dividends over the long run.

Woolworths Group Ltd (ASX: WOW)

A third ASX share that could be a strong addition to a retirement portfolio is supermarket giant Woolworths.

While supermarkets may not seem exciting, Woolworths' strength lies in how it continues to evolve a very traditional business model.

Beyond its core grocery operations, the company has been investing in areas such as supply chain automation, data analytics, and retail media. These initiatives are helping it improve efficiency, deepen customer engagement, and unlock new revenue streams.

At the same time, Woolworths benefits from a structural advantage that few companies can match. Food and everyday essentials are non-discretionary purchases, which means demand remains relatively resilient even during economic downturns.

For retirement investors seeking a blend of stability, modest growth, and dependable income, Woolworths could offer a defensive backbone that can help balance a broader portfolio.

The post 3 of the best ASX retirement shares to buy now appeared first on The Motley Fool Australia.

That has been enough to shake confidence in parts of the market. Headlines have turned more cautious, and it is easy to focus on what could go wrong next.

But I think periods like this are worth looking at differently.

For long-term investors, pullbacks can create the conditions for building wealth.

Lower ASX share prices change the equation

When share prices fall, future return potential improves. 

That is a simple idea, but an important one.

A number of quality ASX shares are now trading well below their recent highs. Businesses like CSL Ltd (ASX: CSL), James Hardie Industries PLC (ASX: JHX), and Cochlear Ltd (ASX: COH) have seen significant declines, even though their long-term growth drivers remain in place.

That does not mean they will rebound immediately.

But starting from a lower entry point can make a big difference over time.

Short-term concerns are driving sentiment

There are clear reasons behind the recent selloff.

Rising oil prices, driven by tensions in the Middle East, have increased concerns about inflation and interest rates. At the same time, ongoing debates around artificial intelligence are creating uncertainty in parts of the technology sector.

These are real factors.

But markets tend to react quickly to uncertainty, sometimes more quickly than the underlying fundamentals change.

In many cases, I think what we are seeing is sentiment adjusting faster than business performance.

This is how long-term returns are built

Looking back, some of the best investment periods have followed market weakness.

The COVID-19 selloff in 2020 is a good example. Investors who were willing to buy during that period were often rewarded as markets recovered.

I am not suggesting that every downturn plays out the same way.

But I do think the principle holds.

Buying quality ASX shares when prices are lower can improve long-term outcomes, particularly if you remain invested and allow compounding to work.

Staying consistent matters more than timing

Trying to pick the exact bottom is extremely difficult. It usually becomes obvious only after the fact.

That is why I prefer a more consistent approach.

Adding to investments during periods of weakness, rather than waiting for perfect conditions, can help build positions over time without relying on a single decision.

Focus on quality

Not every ASX share that falls is an opportunity. Some declines reflect real challenges.

That is why I think it is important to focus on quality.

Businesses with strong balance sheets, competitive advantages, and clear growth drivers are more likely to recover and continue compounding over time.

For me, that is where the real opportunity lies during a selloff.

Foolish takeaway

The recent ASX share market selloff may feel uncomfortable, but I think it also creates opportunity.

Lower prices can improve long-term return potential, especially when applied to high-quality businesses.

There will always be uncertainty in markets.

But for investors with a long-term mindset, periods like this can be some of the most important times to stick with it and continue building positions.

The post Why the recent ASX share market selloff is a wealth-building opportunity appeared first on The Motley Fool Australia.

But when I break it down, it becomes far more manageable.

It is not about finding the perfect ASX share or timing the market. It is about consistency, patience, and leveraging the power of compounding.

The maths behind it

Let's start with a simple assumption.

If you can achieve an average return of 9% per year, which I think is a reasonable long-term expectation for a diversified portfolio of ASX shares, although not guaranteed, the path to $1 million becomes clearer.

At that return, investing $5,000 per year would grow to roughly $1 million in just over 33 years.

Clearly this is not a one-off effort. It is a habit. A system that builds momentum over decades.

And once that momentum builds, the numbers can start to accelerate in ways that are hard to appreciate early on.

The early years feel slow

In the beginning, progress can feel underwhelming. After five years, you have contributed $25,000. The portfolio might be worth a bit more than that, but not dramatically so.

This is where a lot of people lose interest. But I think this is the most important phase.

Because what you are really building early on is not wealth. It is discipline.

You are learning to invest regularly, ignore short-term noise, and stay focused on the long term.

Then compounding starts to show up

As the portfolio grows, something changes. The returns begin to matter more than the contributions.

At some point, your portfolio might grow by more in a year than you are adding yourself.

That is when compounding really starts to work in your favour.

And from there, the process becomes less about how much you can contribute and more about how long you can stay invested.

Which ASX shares I would invest in

If I were building a portfolio like this, I would keep things simple.

I would focus on high-quality ASX shares that have the potential to grow earnings over time and deliver a mix of capital growth and income.

This might mean companies like Goodman Group (ASX: GMG), ResMed Inc. (ASX: RMD), and Cochlear Ltd (ASX: COH) for exposure to global growth themes.

At the same time, businesses such as TechnologyOne Ltd (ASX: TNE) and WiseTech Global Ltd (ASX: WTC) provide exposure to high-margin software models with recurring revenue.

And I would likely balance that with more established names like Commonwealth Bank of Australia (ASX: CBA) and Telstra Group Ltd (ASX: TLS), which can provide stability and income along the way.

The exact mix is less important than the principle. Own quality businesses and give them time.

Foolish takeaway

Building a million-dollar ASX share portfolio from zero is not about luck or timing. It is about consistency and time.

A steady investment of $5,000 per year, combined with a long-term return of around 9%, could get you there over a few decades.

It may not feel exciting in the early years. But over time, compounding can turn small, consistent steps into something significant.

The post How to build a million-dollar ASX share portfolio from zero appeared first on The Motley Fool Australia.

In fact, periods of uncertainty often see investors pull back from even the most established names. While that can be uncomfortable in the short term, it can also create opportunities to buy leading businesses at more attractive prices.

Here are three ASX blue chips that have fallen heavily and could be worth a closer look.

Cochlear Ltd (ASX: COH)

The first ASX blue chip that could be too cheap to ignore is Cochlear.

The hearing solutions company recently disappointed the market with a softer-than-expected result, driven in part by a slower rollout of its new Nexa system and margin pressure from product mix.

While this has weighed on sentiment, it does not change Cochlear's long-term position as a global leader in implantable hearing devices.

Demand for hearing solutions continues to grow due to ageing populations and increased awareness. Cochlear also benefits from a large installed base, which generates recurring revenue through upgrades and servicing.

If the company can execute on its product rollout and return to stronger growth, the current weakness could prove temporary.

CSL Ltd (ASX: CSL)

Another ASX blue chip that may be worth considering is CSL.

The biotech giant's shares have fallen sharply following a soft result and the unexpected CEO transition, which has created uncertainty around its near-term outlook.

The key issue has been weaker-than-expected performance in its CSL Behring division, particularly in immunoglobulin, alongside slower margin recovery than the market had anticipated.

However, CSL still operates in global healthcare markets with strong demand and high barriers to entry. Its therapies address serious medical conditions, and long-term growth drivers remain intact.

While challenges remain, the company's track record and market position suggest it has the capability to work through this period and return to more consistent growth.

James Hardie Industries plc (ASX: JHX)

A third ASX blue chip that could be trading at an attractive level is James Hardie Industries.

The building materials company has been under pressure due to concerns about housing market weakness, particularly in the United States.

Slower construction activity can weigh on demand for its fibre cement products, which has led to more cautious sentiment from investors.

However, James Hardie remains a leader in its category, with strong brand recognition and a history of gaining market share over time.

When housing activity eventually recovers, the company could be well placed to benefit. In the meantime, it continues to focus on innovation and expanding its product offering.

For investors willing to look beyond the near-term uncertainty, this could make it an interesting option at current levels.

The post Are these ASX blue chips now too cheap to ignore? appeared first on The Motley Fool Australia.

But does the broker think they are buys, holds, or sells? Let's see what it is saying about them:

Cochlear Ltd (ASX: COH)

This hearing solutions company delivered a result that was below expectations during the first half of FY 2026.

And while the broker notes that demand for the new Nucleus Nexa system is increasing, it isn't enough for a buy rating at this point. It has put a hold rating and $214.93 price target on its shares. However, this is comfortably ahead of the current Cochlear share price of $172.36. It said:

The 1H26 result was softer than expected, with revenue, margins and profit negatively impacted mainly on longer than anticipated contracting for the newly launched Nucleus Nexa system (Nexa). Soft Cochlear Implants (CI) growth mis-matched sales, reflecting unfavourable emerging market mix and delayed developed market momentum, while Services was flat and Acoustics surprised to downside on increased competitive pressures.

While Nexa adoption accelerated late in the half and management maintained FY26 guidance, but now is targeting the lower end of the range, it increases reliance on a strong 2H recovery which appears optimistic, especially in light of flat GM and FX headwinds. We adjust our FY26-28 estimates and lower our target price to A$214.93. We maintain a cautious stance, but move to HOLD on share weakness.

South32 Ltd (ASX: S32)

Unlike Cochlear, this mining giant outperformed expectations during the first half.

While Morgans was impressed with its result, due to its current valuation, it has lowered its rating to accumulate with a $5.00 price target. This compares to the latest South32 share price of $4.42. It said:

Bumper 1H26 EBITDA comfortably ahead of consensus and close to our estimate, riding consistent production and higher base and precious metals. 15% interim dividend beat and upsized capital management of an extra US$100m. Not all positive, Hermosa budget increase flagged for H2 a ST risk to monitor. Guidance unchanged, besides Brazil Aluminium output and capex timing tweaks.

We lower our rating to ACCUMULATE (from BUY) with an unchanged A$5.00 TP, recommending patience when adding following the recent share price surge.

Westpac Banking Corp (ASX: WBC)

Finally, Morgans has been looking at Westpac shares following its first-quarter update.

Although the broker was pleased with the update, it has only been enough to upgrade its shares to a trim rating (between sell and hold) with a $35.12 price target. This compares to the latest Westpac share price of $39.85. It said:

A largely stable 1Q26 result compared to the 2H25 quarterly average (normalised for 2H25's restructuring charge), which is better than 1H26 expectations. We are assuming a more bullish loan growth and impairments outlook than previously (and slightly more conservative costs).

There is no change to FY26F EPS but there are 5-8% upgrades to FY27-28F. Target price lifts to $35.12/sh. We upgrade to TRIM given the improved, but still negative, potential TSR.

The post Buy, hold, sell: Cochlear, South32, and Westpac shares appeared first on The Motley Fool Australia.

But big sell-offs can create big opportunities, especially when the long-term story remains intact.

Here are three ASX shares down 25% or way more that could be worth a serious look right now.

Pro Medicus Ltd (ASX: PME)

This $12 billion ASX share has been hammered, with the stock price down more than 38% over the past year. Yet the underlying business remains elite.

Pro Medicus provides radiology imaging software to hospitals and healthcare providers globally. It serves a niche, high-margin space with strong recurring revenue. Its Visage platform is widely regarded as best-in-class, giving it a powerful competitive moat.

Growth has been strong historically, driven by major contract wins in the US. And once hospitals adopt its system, switching costs are extremely high.

So what's the risk?

Valuation — even after the fall. Pro Medicus has long traded at a premium, and any slowdown in contract wins or growth can hit sentiment hard. Add in broader tech sector weakness and AI fears, and you've got a recipe for volatility.

Analyst sentiment remains broadly positive, with many still viewing the ASX share as one of the highest-quality growth names on the ASX. Most brokers see the healthcare stock as a buy with an average 12-month price target of $218.74. That points to a 76% upside at the time of writing.

James Hardie Industries plc (ASX: JHX)

James Hardie shares are down heavily from recent highs, caught in the downturn in US housing. They have lost 25% of value over 12 months.

But this ASX share is still a dominant global player in fibre cement siding, with strong pricing power and a proven ability to grow market share.

Recent results showed solid sales growth, even as costs and housing softness impacted profits. And the AZEK acquisition opens the door to a much larger outdoor living market.

The risks? Cyclicality.

James Hardie is highly exposed to US housing activity. If housing remains weak, volumes and earnings could stay under pressure.

That said, analysts remain constructive. Trading View data show that 15 out of 22 analysts rate the ASX share a buy or strong buy. They have set an average price target of $42.09, implying a potential gain of almost 50% for the next 12 months.

Cochlear Ltd (ASX: COH)

This popular ASX share has also fallen sharply from its highs, dragged down by margin concerns and softer growth expectations. In the past 12 months it has tumbled 34% to $175.04 at the time of writing.

But the long-term story remains compelling.

Cochlear is the global leader in implantable hearing devices, with a dominant market position and strong brand recognition. Demand is underpinned by ageing populations and increasing awareness of hearing solutions. That's a powerful structural tailwind.

Its products are also highly specialised, which creates strong barriers to entry and leads to sticky customer relationships.

So why the sell-off?

Margins and growth have come under pressure, and investors have been quick to re-rate high-PE healthcare names. Like many quality ASX shares, this stock has suffered from multiple compression rather than a collapse in fundamentals.

Analysts remain broadly positive. They seem to be more cautious though in the near term as the company works through cost pressures and growth expectations reset. The average 12-month price target sits at $249.58, which suggests a 43% upside.

The post 3 ASX shares down 25% (or more) to buy right now appeared first on The Motley Fool Australia.

Sometimes that decline is warranted. Sometimes it is an overreaction and opens up opportunities for investors willing to take a longer-term view.

Right now, there are a number of ASX 200 shares trading well below their recent highs. Here are three that I think are worth considering.

Qantas Airways Ltd (ASX: QAN)

Qantas has pulled back around 32% from its 52-week high, and I think that is starting to look very interesting.

Airlines are never simple investments. Fuel costs, economic conditions, and operational risks can all impact earnings quickly. With oil prices recently pushing above US$100 per barrel, it is easy to see why sentiment has softened.

But when I step back, I still see an ASX 200 share that is structurally stronger than it was a few years ago.

Qantas operates in a relatively rational domestic market, supported by a duopoly structure. Its loyalty division continues to provide a high-margin earnings stream, and the ongoing fleet renewal program should help improve efficiency over time.

To me, this looks like a case where short-term concerns are weighing on a business that still has a solid long-term foundation.

DroneShield Ltd (ASX: DRO)

DroneShield is down roughly 40% from its high, and that volatility is not unusual for a company of its size and growth profile.

What stands out to me with DroneShield is the underlying theme. The use of drones in both military and civilian settings is expanding rapidly. With that comes a growing need for counter-drone technology, which is exactly where DroneShield is focused.

This is a market that is still evolving, but I think the direction is clear.

Governments and organisations are increasing their focus on security, surveillance, and defence capabilities. Technologies that can detect and respond to drone activity are becoming more important.

There will likely be ups and downs along the way, particularly as contracts and funding cycles play out. But over a longer period, I think the opportunity set remains compelling.

Cochlear Ltd (ASX: COH)

Lastly, Cochlear has fallen around 45% from its highs, which is a significant move for a company that has historically been viewed as a high-quality defensive growth business.

The recent weakness reflects a combination of factors, including softer earnings and broader market pressure on healthcare stocks.

But I do not think the core story has changed.

Cochlear operates in a specialised area of medical technology with high barriers to entry. Its products address a critical need, and demand is supported by long-term trends such as ageing populations and increased awareness of hearing health.

What I like is the combination of innovation and global reach. This is an ASX 200 share that continues to invest in new products and expand its footprint internationally. That gives it the potential to grow over time, even if the path is not always smooth.

Foolish takeaway

Not every share that falls 30% or more is a buying opportunity. But I think it is worth paying attention when established businesses and emerging growth companies are trading well below their recent highs.

Qantas, DroneShield, and Cochlear are very different businesses, each with their own risks and drivers. What they have in common is that sentiment has weakened, while their long-term potential still appears intact. For me, that is often where the most interesting opportunities start to appear.

The post 3 ASX 200 shares down at least 30% to buy now appeared first on The Motley Fool Australia.

This can scare many investors off. But there are signs that now could actually be the best time to buy ASX shares.

Optimism crept back into the market this week, with the S&P/ASX 200 Index rising 2.2% on Wednesday amid hopes that the war in the Middle East could soon come to an end.

While one strong session does not confirm a trend, it can signal a change in tone.

ASX share valuations still look compelling

What makes the current setup particularly interesting is that many high-quality ASX 200 shares are still trading well below their previous highs.

This includes names like CSL Ltd (ASX: CSL), ResMed Inc. (ASX: RMD), Cochlear Ltd (ASX: COH), Pro Medicus Ltd (ASX: PME), Xero Ltd (ASX: XRO), and WiseTech Global Ltd (ASX: WTC).

These are not speculative businesses. They are established companies with strong competitive positions, global exposure, and long-term growth drivers. Yet despite this, their share prices have pulled back materially in recent periods.

That disconnect between business quality and share price performance is often where opportunity begins to emerge.

Markets move before confidence returns

One of the challenges with investing is that markets are forward-looking.

By the time the outlook feels clear and positive, share prices have usually already moved higher. In contrast, when uncertainty is still present but conditions are beginning to stabilise, valuations can remain relatively attractive.

This creates a window where the risk-reward balance for ASX shares may be more favourable.

It is not about picking the exact bottom. That is almost impossible to do consistently. Instead, it is about recognising when sentiment is shifting while prices still reflect a degree of caution.

Why long-term investors pay attention to these moments

For long-term investors, these periods can be particularly important.

Buying high-quality ASX shares when they are out of favour but still executing well has historically been one of the more reliable ways to build wealth over time.

Of course, risks remain. Economic conditions are still mixed and geopolitical uncertainty has not disappeared. But markets do not wait for perfect clarity before moving. They tend to turn when expectations are low and begin to improve.

That is why now could be the time to consider buying ASX shares. Sentiment may be shifting, but many opportunities are still on the table.

The post The best time to buy shares? It might be right now appeared first on The Motley Fool Australia.

Healthcare shares are facing many headwinds, as portfolio managers Joe Koh and Elan Miller from Blackwattle explain:

The sector as a whole has faced multiple headwinds, including currency and tariffs for the large multinationals and labour and cost pressures for the domestic players.

Today, eight of the 10 largest ASX 200 healthcare shares are trading at or close to multi-year or 52-week lows.

Does this present a buying opportunity?

Let's see what the experts say about three of these ASX 200 healthcare shares.

Sonic Healthcare Ltd (ASX: SHL)

The Sonic Healthcare share price fell to a decade-low of $19.57 last week.

This ASX 200 healthcare share has fallen 9.7% in the year to date (YTD) and 21.3% over the past year.

Last week, Ord Minnett issued a new note on Sonic Healthcare shares.

The broker maintained its hold rating with an unchanged target of $24.

Ord Minnett commented:

Ord Minnett finds it difficult to be constructive on Sonic given its inability to generate meaningful organic growth even after $3.3 billion of acquisitions over the past seven years.

There are undoubtedly some benefits from M&A, but other factors, such as price cuts and customer quotas specific to heathcare in its various markets, along with run-of-the mill costs such as wages and rents, appear to have constrained any meaningful earnings growth.

This view leads us to maintain our Hold recommendation despite the apparent value on offer.

Cochlear Ltd (ASX: COH)

The Cochlear share price tumbled to a six-year low of $160 last week.

This ASX 200 healthcare share has fallen 36.1% YTD and 36.4% over the past year.

Wilsons says Cochlear shares are trading at "a compelling entry point".

The broker commented:

Cochlear trades on a forward P/E multiple of ~26x, representing a >10 year low and a material discount to its 10-year average of ~42x.

We view this as a compelling entry point for a high-quality business ahead of accelerating earnings growth.

Wilsons expects the launch of Cochlear's Nucleus Nexa product to drive sales growth over the medium term.

Cochlear is approaching an inflection point in its earnings growth trajectory, supported by the ongoing global rollout of Nucleus Nexa (approved in mid-2025), which is its most significant product launch in over two decades.

Nexa's upgradeable firmware architecture represents a step-change in implant technology, enabling ongoing improvements in sound processing, connectivity and battery life via its Smart Sync app.

The rollout over the next few years should support ~10% CI unit growth over the medium term, with potential upside toward the mid-teens, while recurring implant upgrades will extend the Nexa's product cycle, supporting a longer duration of growth.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price crumbled to a two-year low of $107.75 late last month.

This ASX 200 healthcare share has fallen 49.3% YTD and 43.5% over the past year.

Pro Medicus shares are experiencing a period of correction after a ripsnorting two-year run through to mid 2025.

The Pro Medicus share price hit a record $336 per share in July last year.

Bell Potter has a buy rating and $240 price target on Pro Medicus shares.

The broker explains:

The company continues to announce new contract wins on a regular basis as the drivers of interest in its product offering remain firmly in place. The entire radiology industry is headed to cloud based (off premises) archiving. Put simply, the Visage 7 viewer, Workflow and Archive are the fastest and most advanced tools for the retrieval and viewing of large radiology files.

The platform is immensely scalable and relatively easily installed, providing it with a sustainable competitive advantage over the likes of peers Intelerad, Sectra, Philips and GE Healthcare. The company is conservatively managed and well owned by large institutional investors while the two founders continue to have a controlling stake.

The post 3 ASX 200 healthcare shares at multi-year lows appeared first on The Motley Fool Australia.

Prices are falling, headlines are negative, and sentiment is weak. 

But in my opinion, this can sometimes be the best time to make a move.

A market creating opportunities beneath the surface

The broader share market has underperformed in recent months, but has not fallen dramatically.

The S&P/ASX 200 index (ASX: XJO) is down around 8.4% from its recent high, which is noticeable but not extreme.

But that does not tell the full story.

Beneath the surface, a number of ASX shares have been sold off heavily. In many cases, far more than the overall market.

And when I see that kind of divergence, I start paying attention.

Why buying cheap ASX shares can matter

Buying ASX shares after they have fallen significantly can provide something that I think is incredibly valuable.

A margin of safety.

If expectations are already low and sentiment is weak, it does not take much for things to improve. And when they do, share prices can move quickly.

That is where the potential for outsized returns comes from.

Of course, not every fallen share is a good opportunity. Some deserve to be down.

But when high-quality businesses are caught up in broader sell-offs, I think that is where things get interesting.

Where I am seeing value today

There are quite a few ASX shares that have pulled back sharply over the past year.

Online retailer Temple & Webster Group Ltd (ASX: TPW) is down around 58%. Healthcare giant CSL Ltd (ASX: CSL) has fallen roughly 42%.

Radiopharmaceutical company Telix Pharmaceuticals Ltd (ASX: TLX) is down about 50%, while footwear retailer Accent Group Ltd (ASX: AX1) has dropped close to 60%.

Even high-quality industrial names like James Hardie Industries Plc (ASX: JHX) and Cochlear Ltd (ASX: COH) are down around 35% and 37%, respectively.

These are not small moves.

And while each company has its own reasons for falling, I think it is important to recognise the broader context as well.

What is driving the sell-off?

There are a few key factors at play.

The conflict in the Middle East has pushed oil prices above US$100 per barrel, which is raising concerns about inflation and the potential for higher interest rates.

At the same time, artificial intelligence (AI) disruption concerns have been weighing on parts of the market, particularly software and growth stocks.

Put that together and you get a market that is more cautious, more selective, and in some cases, more pessimistic.

But I do not think that necessarily reflects the long-term outlook for many of these businesses.

Lessons from the past

One thing I often think about is how investors behaved during the COVID crash in 2020.

At the time, fear was widespread and uncertainty was high. But for those who were willing to step in and buy quality ASX shares at depressed prices, the returns that followed were significant.

I am not suggesting this is the same situation. But I do think the principle still applies.

Periods of weakness can create opportunities for long-term investors who are willing to look beyond the short-term noise.

The importance of a long-term mindset

If I am buying ASX shares that have fallen sharply, I am not doing it for a quick rebound.

I am doing it with a long-term mindset.

Some of these companies may take time to recover. There could be more volatility ahead. And not all of them will bounce back in a straight line.

But if the underlying businesses remain sound and continue to execute, I think the next decade could look very different from the past 12 months.

Foolish takeaway

Buying dirt-cheap ASX shares is not about chasing falling prices.

For me, it is about identifying quality businesses that have been caught up in broader sell-offs and buying them at more attractive levels.

With many ASX shares down significantly and the market off its highs, I believe there are opportunities available for patient investors.

The post Why I'd buy dirt-cheap ASX shares now and aim to hold them for a decade appeared first on The Motley Fool Australia.

Here are three worth considering for your set-and-forget investing portfolio.

Washington H. Soul Pattinson and Co Ltd (ASX: SOL)

While the name is often thought of in terms of the pharmacies, the company divested its last remaining interests in the retail chain in 2020. Today, it is an investment company that owns a portfolio designed to build wealth steadily over time.

In 2025, it completed a merger with building materials manufacturer Brickworks Limited, ending five decades of cross-shareholdings between the companies. The new arrangement created a $14 billion investment powerhouse, further improving liquidity and transparency.

Why is Washington H. Soul Pattinson a solid ASX dividend share?  

Soul Patts' diversification across multiple uncorrelated sectors is its defensive moat. Diversification on this scale smooths earnings, reduces volatility, and allows long-term capital allocation.

The model is a simple one – a long-running investment conglomerate that invests in high-quality businesses and compounds capital, and it is in a robust financial position. Soul Patts holds pre-tax net assets of $13.5 billion as at 1H26, up 14.6% on the prior corresponding period (PCP). And cash holdings of $427 million, providing resiliency if things go wrong. However, the scale of its diversification also gives it ample coverage here.

As for its growth runway, Soul Patts invests in both listed and unlisted businesses across the globe, providing almost limitless investment opportunity. And it remains a family-run enterprise, despite its scale, so management skin in the game is apparent too.

And when it comes to returns, Soul Patts comes through here too. It has paid dividends every year since it listed on the ASX over a century ago. And every year for the last 27 years, the dividend has grown year on year.

You will pay a premium, but the valuation is justified for set-and-forget investors given its solid track record and high-quality balance sheet.

Cochlear Ltd (ASX: COH)

Cochlear is a global leader in implantable hearing solutions, with a market share of around 60% in developed markets. It has solid recurring revenue streams too, with patients returning for upgrades or device accessories.

Why is Cochlear a solid ASX dividend share?

A quality, trusted healthcare product that makes meaningful change in people's lives creates customer stickiness — patients often stay in the Cochlear ecosystem. Its global reputation and position in a tightly regulated market give it a solid defensive moat, and its balance sheet remains resilient despite some challenges of late.

Its business model is easy to understand — we all know what Cochlear does. Today, more than 1 million people across the globe use a Cochlear device. And with an aging population, the demand for hearing devices is set to increase in the coming years, creating a growth runway. It is also a known innovator, consistently investing in Research & Development. As technology advances, I believe Cochlear will remain at the forefront.

However, it has faced some setbacks of late, which has seen the share price fall 37% in the last twelve months. Delays in transitioning patients to its new Nucleus Nexa device have contributed to underlying net profits falling 9%, missing analysts' expectations.

That said, it retains strong cash holdings, with operating cash flow increasing by $26.9 million to $136.8 million and free cash flow up by $24 million to $82.7 million in its 1H26 reporting.

It also recently announced a dividend of $2.15, flat against the prior corresponding period. While this has some worried that it might signal the end of steadily increasing dividends for the healthcare leader, I think it will bounce back in the second half as the Nucleus Nexa rollout regains momentum.

For me, recent conditions have created an opportunity for set-and-forget investors to get in on a market leader at an attractive price.

Brambles Ltd (ASX: BXB)

Brambles operates CHEP, the world's largest pallet-pooling network, providing reusable pallets, crates, and containers used across the globe. Its model creates a cost-effective and efficient circular logistics solution for manufacturers and retailers, and its service is widely considered the benchmark in pallet pooling.  

Why is Brambles a solid ASX dividend share?

Brambles has a classic defensive moat built on scale, network effect, and customer stickiness. The scale of its services means it is disruptive and difficult for customers to switch, and given the quality of its service, they have little incentive to consider a move.

While global logistics is complex, its business is relatively simple. Brambles rents shipping pallets to its customers, collects, repairs, reissues, and repeats. This circular model gives it largely predictable cash flows.

Brambles 1H26 reporting showed a resilient balance sheet with sales revenue and underlying profit increasing, and free cash holdings of US$481.7 million, up $52.5 million on 2025. It also reported an interim dividend of US$0.23 per share, up 21% on FY25.  

These results are particularly strong in the current global climate, with demand headwinds in some markets and increasing inflation-driven cost pressures. 

While it has a moderate to high price-to-earnings (P/E) ratio, I think you are paying for quality here. With solid dividends, a wide defensive moat, and a resilient balance sheet, the current share price represents fair value for set-and-forget investors, in my view.  

The post 3 reliable ASX dividend shares for set-and-forget investing appeared first on The Motley Fool Australia.

But I don't think that is necessarily true.

Simple investing

I believe one of the most realistic ways to get to $1 million is surprisingly simple. 

It involves investing consistently, staying patient, and letting compounding do the hard work.

Let's say you invest $5,000 into ASX 200 shares each year and earn an average total return of 9% per annum. Based on that, it would take a little over 33 years to reach $1 million.

That is a long time. But this isn't about getting rich quickly. It is about building wealth steadily and deliberately over time.

The power of consistency

What stands out to me in this scenario is not the return assumption. It is the consistency.

Putting $5,000 into the market each year might not feel life-changing in the short term. In the early years, the portfolio will grow slowly, and it can feel like progress is limited.

But over time, your returns begin generating their own returns. Then those returns generate even more returns. Eventually, compounding starts to take over in a meaningful way.

I think this is where many investors underestimate what is possible. The real growth tends to come later, not at the beginning.

Backing quality ASX 200 shares

Of course, the 9% return assumption isn't guaranteed, but it is possible.

You set yourself up to have a chance of achieving it by owning a portfolio of strong, growing businesses over a long period of time. And in my view, the ASX 200 offers plenty of shares that could help deliver that.

For example, a company like Goodman Group (ASX: GMG) gives exposure to global logistics and data centre infrastructure, which I believe are supported by long-term structural trends.

Healthcare names such as ResMed Inc. (ASX: RMD) and Cochlear Ltd (ASX: COH) operate in areas with growing demand and, in my opinion, strong competitive advantages.

Then there are technology and software businesses like TechnologyOne Ltd (ASX: TNE), Pro Medicus Ltd (ASX: PME), and WiseTech Global Ltd (ASX: WTC). These companies have delivered strong growth historically, and I think they highlight how innovation can drive long-term returns.

Even more traditional names like Commonwealth Bank of Australia (ASX: CBA) or Telstra Group Ltd (ASX: TLS) can play an important role, particularly when it comes to income and stability.

I believe a mix of these types of businesses can help create a balanced portfolio that has the potential to compound over time.

Time in the market matters most

One thing I have learned is that waiting for the perfect moment to invest can be a costly mistake.

Markets will always give you reasons to hesitate. There will be volatility, corrections, and headlines that make investing feel uncomfortable.

But if the goal is to invest $5,000 each year for decades, I think consistency matters far more than timing.

Some years you will invest at higher prices. Other years you will invest during pullbacks. Over time, those decisions tend to average out.

What matters most, in my opinion, is staying invested in ASX 200 shares and continuing to add to your portfolio.

Patience will be required

There is no getting around the fact that 33 years is a long time.

It requires patience and discipline. It also requires sticking with the plan even when markets are not cooperating.

But when I look at the alternative, trying to chase quick gains or jumping in and out of the market, I think the long-term approach is far more reliable.

And importantly, it is repeatable.

You do not need to predict the next big winner. You just need to consistently invest in quality ASX 200 shares and give them time to grow.

Foolish takeaway

Turning $5,000 a year into $1 million is not about luck. It is about consistency, quality, and time.

By investing regularly into ASX 200 shares and aiming for a long-term return of around 9% per annum, I believe reaching that milestone is achievable, even if it takes a little over three decades.

It might not be exciting in the early years. But over time, compounding can turn a simple plan into something very powerful.

The post How to become a millionaire with a $5,000 investment in ASX 200 shares each year appeared first on The Motley Fool Australia.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:

Breville Group Ltd (ASX: BRG)

According to a note out of Macquarie, its analysts have retained their outperform rating on this appliance manufacturer's shares with a trimmed price target of $37.10. Macquarie has been looking at industry data and believes it is favourable for Breville and suggests that it could be outperforming peers. The broker highlights that this is being driven by growth from its coffee business, as well as new products and new markets. Overall, Macquarie believes this leaves Breville well-placed for annual growth of 10%+ through to FY 2028. The Breville share price ended the week at $26.28.

Cochlear Ltd (ASX: COH)

A note out of UBS reveals that its analysts have retained their buy rating and $302.00 price target on this hearing solutions company's shares. UBS believes that recent share price weakness has created an attractive buying opportunity for investors. This is especially the case given how the broker believes Cochlear's new next-generation cochlear implant platform, Nexa, will underpin a strong earnings recovery. The broker believes that with limited competition, Cochlear is well-placed to win market share. And while there are concerns over gene therapies, UBS doesn't believe this is something that will impact its near term performance. The Cochlear share price was fetching $170.23 at Friday's close.

Liontown Ltd (ASX: LTR)

Another note out of UBS reveals that its analysts have retained their buy rating and $2.20 price target on this lithium miner's shares. UBS is feeling positive about lithium and believes now could be a good time for investors to consider a position in the industry. This is because UBS sees potential for another upcycle for lithium prices. It suspects that surging oil prices and supply disruptions caused by the war in the Middle East could be good news for lithium. It feels that the impact this is having on the fuel market could lead to increased demand for electric vehicles and lithium for batteries. In fact, the broker sees potential for the spodumene price to reach US$4,000 per tonne by the end of the year. The Liontown share price ended the week at $1.76.

The post Top brokers name 3 ASX shares to buy next week appeared first on The Motley Fool Australia.

While that is disappointing for our portfolios, the short term pain could have created some compelling buying opportunities.

But which ASX 200 shares are buys? Let's take a look at five that Wilsons thinks have been oversold.

Wilsons says these ASX 200 shares have been oversold

Wilsons highlights that ASX growth shares and those linked to financial markets have undertaken a major de-rating.

This includes hearing solutions company Cochlear Ltd (ASX: COH), investment platform provider Hub24 Ltd (ASX: HUB), and investment management company Pinnacle Investment Management Group Ltd (ASX: PNI).

Wilsons points out that these ASX 200 shares are now trading on lower than average PE ratios despite having positive outlooks. It explains:

Growth stocks and companies with earnings leverage to financial markets have de-rated as bond yields have risen and risk assets weakened, creating selective opportunities on a medium-term view. Pinnacle (PNI) and HUB24 (HUB) trade below five-year average P/E multiples while retaining strong structural growth and offering meaningful leverage to an eventual equity market recovery. Cochlear (COH) trades at a decade-low P/E, with its Nexa product cycle supporting medium-term earnings acceleration.

What else?

Also catching the eye of Wilsons is Amcor (ASX: AMC). Its shares are trading close to 52-week lows despite having defensive qualities and being well-placed for growth from just the synergies of the Berry acquisition. It adds:

Cyclicals outside mining have also weakened on global and domestic growth concerns. We remain cautious on domestic cyclicals given a soft backdrop and RBA tightening but see more compelling opportunities offshore. Amcor (AMC), while arguably a defensive given its consumer staples end-market exposure, has been impacted by cyclical packaging demand concerns. However, it remains well positioned to deliver double-digit EPS growth from Berry synergies alone. On this basis, its single-digit P/E appears attractive.

Finally, Wilsons thinks copper miner Sandfire Resources Ltd (ASX: SFR) is an ASX 200 share that offers an attractive risk/reward following recent weakness in the mining sector. It commented:

The broader mining sector has sold off on cyclical growth concerns. While uncertainty remains elevated, miners appear well placed to rebound if the conflict de-escalates over the next few weeks. Within the sector, Sandfire Resources (SFR) offers an attractive risk/reward, supported by tight copper fundamentals, structural demand tailwinds, and valuation upside.

The post 5 oversold ASX 200 shares to buy according to Wilsons appeared first on The Motley Fool Australia.

Losses have been seen across the board this year as geopolitical uncertainty and concerns about rising inflation rates puts pressure on markets.

But there are some ASX shares which have been pushed down to fresh multi-year lows.

The question is: Is this a buying opportunity for investors? Or a sign of what will come next?

Dexus (ASX: DXS)

At the time of writing, Dexus shares have shed another 1.3% to $5.96 a piece. Today's decline marks the stock's lowest point seen since late-2012. 

The shares have tumbled 14% so far in 2026 and are now down 19% over the year. The decline has come off the back of concerns about Australia's interest rate direction, high borrowing costs, and overall investor uncertainty. 

But the ASX 200 real estate stock is a major Australian property investor, developer, and manager. It has a large, high-grade office portfolio and a smaller industrial portfolio in Australasia. It also manages properties on behalf of third-party investors. 

This means it's diverse and it has a steady, reliable income.

Its FY26 first-half statutory NPAT came in at $348.5 million, up significantly from $10.3 million in the same period last year. The increase was mostly driven by property valuation gains.

Analysts tip an average upside of 22% to $7.28 per share.

Cochlear Ltd (ASX: COH)

Cochlear shares are also trading in the red at the time of writing, down 0.2% to $165.30. This is the lowest level seen for the ASX 200 company's shares since October 2017.

The shares have crashed 37% in the first three months of 2026, and they're 39% lower over the past year.

The world's leading cochlear implant manufacturer suffered from lower-than-expected FY25 results in mid-August, and again for the first half of FY26 last month. Investors were spooked and many sold up their stock.

But brokers are confident that a recovery is on the horizon, with many agreeing that the company's share price is now below fair value.

Analysts tip an average upside of 51% to $249.58 over the next 12 months, at the time of writing.

WiseTech Global Ltd (ASX: WTC)

It's been a bloodbath for WiseTech shares over the past nine months, with the company's share price crashing 68%. At the time of writing, the share price is down another 3% to $38.45, marking the lowest point for the ASX 200 shares since a dip in June 2022.

For the year to date, the shares have shed 44% of their value, and the stock is currently trading 55% below where it was this time last year.

The logistics software company faced several huge headwinds, which sent its value crashing. Even an impressive half-year result in late February didn't stop investors selling up.

But after so much downwards pressure, brokers expect the price to bottom out this year and start soaring.

Analysts tip an average 123% upside to $85.69 over the next 12 months, at the time of writing.

The post These 3 ASX 200 shares have hit fresh multi-year lows: Buy, sell or hold? appeared first on The Motley Fool Australia.